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Essentials
• Recombinant von Willebrand factor (rVWF) is effective
in von Willebrand disease (VWD).
• A phase 3 study of rVWF, with/without recombinant
factor VIII (rFVIII) before surgery in VWD.
• Overall rVWF’s efficacy was rated excellent/good;
rVWF was administered alone in most patients.
• rVWF was well-tolerated and hemostasis was achieved
in patients with severe VWD undergoing surgery.
Summary. Background: Recombinant von Willebrand fac-
tor (rVWF) has demonstrated efficacy for on-demand treat-
ment of bleeding in severe von Willebrand disease (VWD),
warranting evaluation in the surgical setting. Objectives:
This study (NCT02283268) evaluated the hemostatic effi-
cacy/safety profile of rVWF, with/without recombinant
factor VIII (rFVIII), in patients with severe VWD undergo-
ing surgery. Patients/Methods: Patients received rVWF
40–60 IU kg1, VWF ristocetin cofactor activity was mea-
sured 12–24 h before surgery. If endogenous FVIII activity
(FVIII:C) target levels were achieved 3 h before surgery,
rVWF was administered alone 1 h before surgery; rVWF
was co-administered with rFVIII if target endogenous
FVIII levels were not achieved. rVWF was infused postop-
eratively to maintain target trough levels. Overall and intra-
operative hemostatic efficacy, the pharmacodynamics of
rVWF administration and the incidence of adverse events
(AEs) were assessed. Results: All patients treated with
rVWF for major (n = 10), minor (n = 4) and oral (n = 1)
surgery had overall and intraoperative hemostatic efficacy
ratings of excellent (73.3% and 86.7%) or good (26.7%
and 13.3%). Most rVWF infusions (89.4%) were adminis-
tered alone, resulting in hemostatically effective levels of
endogenous FVIII within 6 h, which were sustained for 72–
96 h; 70% (n = 7/10) of major surgeries were performed
without rFVIII co-administration. Six patients reported 12
treatment-emergent AEs. Two patients each had one seri-
ous AE: diverticulitis (not treatment related) and deep vein
thrombosis (sponsor-assessed as possibly treatment
related). No severe allergic reactions or inhibitory antibod-
ies were reported. Conclusions: These data support the effi-
cacy and safety profile of rVWF in patients with severe
VWD undergoing elective surgery.
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Introduction
Von Willebrand disease (VWD), the most common inher-
ited bleeding disorder, is caused by quantitative and qual-
itative defects in von Willebrand factor (VWF) [1,2], a
large multimeric plasma glycoprotein that mediates the
initial adhesion and aggregation of platelets at sites of
vascular injury [1,3,4]. VWF also binds to and stabilizes
coagulation factor VIII (FVIII), thus increasing its half-
life in circulation [1,3–5].
The goal of VWD therapy is to normalize VWF and,
in some cases, FVIII levels [1,2,6]. Approved therapies for
the treatment of VWD include desmopressin, plasma-
derived (pd) VWF/FVIII concentrates and recombinant
VWF (rVWF, VONVENDI [US]/VEYVONDITM [Eur-
ope]; Baxalta, part of Shire, Lexington, MA, USA). As
desmopressin is only effective in some patients with VWD
(e.g. less severe type 1 VWD with a baseline VWF level
of > 10 IU dL1), and repeated closely spaced adminis-
trations may cause tachyphylaxis, replacement therapy is
often used to provide hemostatic efficacy in the surgical
setting [7].
Most pdVWF concentrates contain both VWF and
FVIII, and the ratio between VWF and FVIII in these
products can vary significantly. After repeated dosing of
pdVWF/FVIII concentrates, FVIII accumulation of
> 150% may occur, which has been associated with an
increased risk of thromboembolic events in the surgical
setting [7–9]. Additionally, there are batch-to-batch varia-
tions in VWF ristocetin cofactor activity (VWF:RCo),
and all lack hemostatically effective ultra-large multimers
(ULMs) [3,6,10,11].
rVWF was developed to address some of these limita-
tions. Unlike other concentrates, rVWF replaces missing or
defective VWF, stabilizing endogenous FVIII. Dosing can
be optimized to VWF levels alone, without the concern of
FVIII accumulation, and VWF:RCo activity does not vary
between batches. Additionally, during manufacture, rVWF
is not exposed to ADAMTS-13 and, therefore, contains a
full multimeric profile [11], including the ULMs typically
seen only in platelets and endothelial cells [12].
The efficacy and safety profile of rVWF in on-demand
management of bleeding episodes [13], along with a trend
towards a longer half-life of rVWF compared with
another available concentrate [14], supported further eval-
uation of rVWF in perioperative management of bleeding
in VWD. The goal of this study was to evaluate the
hemostatic efficacy and safety of rVWF (vonicog alfa)
with/without rFVIII (ADVATE [Antihemophilic Factor
(Recombinant); Baxalta, part of Shire, Lexington, MA,
USA], hereafter referred to as rFVIII) in patients with
severe VWD undergoing elective surgery. To better
understand the effects of rVWF administration on
endogenous FVIII activity (FVIII:C) levels a baseline
pharmacokinetics (PK) and pharmacodynamics (PD)
analysis was conducted.
Methods
Study design and patient population
This was a phase 3, prospective, open-label, uncontrolled,
non-randomized study at 14 sites in 10 countries in
patients undergoing major, minor or oral surgery (Clini-
calTrials.gov Identifier: NCT02283268) (Fig. S1). Patients
scheduled for major surgery had an initial PK/PD evalua-
tion over a 72-h period within 42 days of surgery, and
results were used to guide preoperative dosing. The study
was conducted in accordance with the standards of Good
Clinical Practice. The final protocol was approved by the
relevant ethics committees or institutional review boards,
and written informed consent was provided by all partici-
pants.
Patients aged ≥ 18 years with severe VWD of all types
who had planned elective surgery were eligible for the
study. Severe VWD was defined as follows: type 1 (VWF:
antigen [Ag] and VWF:RCo < 20 IU dL1), type 2A
(lack of high-molecular-weight multimers and VWF:RCo/
VWF:Ag < 0.6), type 2B (identification of specific geno-
type), type 2M (presence of all multimers and VWF:RCo/
VWF:Ag < 0.6), type 2N (FVIII:C levels < 10% with
documented genetics) and type 3 (VWF:Ag ≤ 3 IU dL1).
Patients with type 3 VWD had to have a history of ≥ 20
exposure days to VWF/FVIII concentrates (including cry-
oprecipitate or fresh frozen plasma). For patients with
type 1 or type 2 VWD, a minimum of 5 exposure days or
a past major surgery requiring VWF/FVIII-containing
products (including cryoprecipitate or fresh frozen
plasma) was required. Patients were excluded if they
tested positive for VWF or FVIII inhibitors or had a his-
tory of a thromboembolic event, hypersensitivity to
VWF, or any immunologic disorder.
At 12–24 h before surgery, rVWF 40–60 IU kg1
VWF:RCo was given intravenously to allow endogenous
FVIII:C levels to rise to ≥ 30 IU dL1 (minor/oral sur-
gery) or ≥ 60 IU dL1 (major surgery), which were to be
assessed within 3 h of initiation of the surgery. If target
FVIII:C levels were achieved, rVWF alone was adminis-
tered within 1–2 h before surgery to achieve the peak
levels described in Table 1. If target FVIII:C levels were
not achieved, rVWF was co-administered with rFVIII
(ADVATE, Antihemophilic Factor [Recombinant])
within 1–2 h before surgery to meet recommended peak
levels. Intraoperative and postoperative dosing were indi-
vidualized to maintain target trough levels according to
PK/PD results, as well as the intensity and duration of
the hemostatic challenge. Post-surgery, patients were
monitored for 14 days and target trough plasma levels of
VWF:RCo and FVIII:C were maintained according to
the type of surgery the patient received (Table 2).
Major surgeries were defined as those that carried a
significant risk of loss of a large volume of blood or
blood loss into a confined anatomical space, such as
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major orthopedic, abdominal, gynecologic, head and
neck, intracranial, cardiovascular or spinal surgery, and
extraction of impacted third molars. Minor surgical pro-
cedures included placement of intravenous access devices,
removal of small skin lesions, arthroscopy, gastroscopy,
colonoscopy or conization. Oral surgeries included extrac-
tions of < 3 non-molar teeth with no bony involvement.
Antithrombotic prophylaxis was left to the discretion of
the physician.
PK/PD analysis
In 11 patients, the baseline evaluation was completed
using rVWF at a dose of 50  5 IU kg1 VWF:RCo
administered within 42 days before the planned surgery.
PK/PD was assessed before infusion of rVWF and at 0.5,
1, 6, 12, 24, 48 and 72 h post-infusion. PK parameters
(including area under the curve, peak concentration, time
to peak concentration, terminal half-life and incremental
recovery at peak concentration) for VWF:RCo were cal-
culated and analyzed using standard methods. Mean
VWF:RCo and endogenous FVIII:C levels were calcu-
lated over time.
Efficacy evaluations
The primary outcome measure included overall investiga-
tor-assessed hemostatic efficacy of rVWF at 24 h after
the last perioperative infusion or at completion of the
study, whichever occurred earlier, using a four-point rat-
ing scale (‘excellent’, ‘good’, ‘moderate’ or ‘none’) based
on hemostasis relative to a hemostatically normal subject
without VWD (Table S1). Intraoperative hemostatic effi-
cacy was assessed by the surgeon using the four-point effi-
cacy rating scale (Table S1). Intraoperative actual versus
predicted blood loss was also surgeon evaluated.
Safety evaluations
Safety evaluations included the incidence/severity of
adverse events (AEs), thromboembolic events and severe
allergic reactions. Additional diagnostic procedures were
conducted according to the local institution’s medical
standard of care and individual patient risk factors.
Safety evaluations were based on the criteria outlined
in the guideline on the clinical investigation of human
plasma-derived von Willebrand factor products [15]. The
Ristocetin cofactor (VWF:RCo) assay and the FVIII
binding (VWF:FVIIIB) assay were used to test for the
presence of inhibitory anti-VWF antibodies. Neutralizing
antibodies to VWF:RCo and VWF:FVIIIB activities were
assessed by the Nijmegen modification of the Bethesda
assay. Plasma was assayed for the presence of antibodies
against CHO protein (total Ig), murine IgG and human
Furin (total Ig) using proprietary enzyme immunoassays.
Plasma samples were analyzed for binding antibodies
to VWF, CHO protein, murine protein and Furin protein
at the Charite Universit€atmedizin in Berlin, Germany.
Tests to confirm the presence of inhibitory antibodies to
FVIII and VWF were performed in the Department of
Medical and Chemical Laboratory Diagnostics at the
Medical University of Vienna, Austria.
Table 1 VWF:RCo and FVIII:C target levels: recommendations for the prevention of excessive bleeding during and after surgery
Type of surgery
VWF:RCo target peak
plasma level, IU dL1
FVIII:C target peak
plasma level*, IU dL1
Calculation of rVWF dose,
IU VWF:RCo received†
Minor/oral 50–60 40–50 DVWF:RCo 9 BW (kg)/IR‡
Major 100 80–100 DVWF:RCo 9 BW (kg)/IR‡
DVWF:RCo = target peak plasma VWF:RCo – baseline plasma VWF:RCo; BW, body weight; FVIII:C, factor VIII activity; IR, incremental
recovery; rFVIII, recombinant factor VIII; rVWF, recombinant von Willebrand factor; VWF:RCo, von Willebrand factor ristocetin cofactor
activity. *Additional rFVIII may be administered to attain the recommended FVIII:C target peak plasma levels. These levels are in accordance
with those outlined in the guideline on the core SPC for human plasma derived von Willebrand factor (CPMP/BPWG/278/02) [24]. †Adminis-
tered within 1–2 h before surgery. ‡If the IR is not available, assume an IR of 2.0 IU dL1 per IU kg1.
Table 2 Target VWF:RCo and FVIII:C trough plasma level and minimum duration of treatment recommendations for subsequent mainte-
nance doses for the prevention of excessive bleeding during and after surgery
Type of surgery
VWF:RCo trough plasma level FVIII:C trough plasma level
Minimum duration
of treatment Frequency of dosing
Up to 72 h
post-surgery
After 72 h
post-surgery
Up to 72 h
post-surgery
After 72 h
post-surgery
Major > 50 IU dL1 > 30 IU dL1 > 50 IU dL1 > 30 IU dL1 72 h Every 12–24 h to every other day
Minor ≥ 30 IU dL1 – > 30 IU dL1 – 48 h Every 12–24 h to every other day
Oral ≥ 30 IU dL1 – > 30 IU dL1 – 8–12 h Every 12–24 h to every other day
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Statistics
It was planned to have a minimum of 15 patients with
severe VWD who were undergoing surgery, with ≥ 10
major surgical procedures evaluated. Descriptive statisti-
cal analyses included point estimates and 90% confidence
intervals (CIs) for the incidence of individuals with hemo-
static efficacy rated ‘excellent/good’ and were determined
using a Clopper Pearson test and SAS v9.4. PK/PD and
safety were summarized using descriptive statistics.
Results
Patient disposition and baseline characteristics
A flow chart of patient selection is shown in Fig. S2.
Patient demographics and baseline clinical characteristics
are summarized in Table 3. Major surgeries were per-
formed in 10 patients (66.7%), minor surgeries in four
patients (26.7%) and oral surgery in one patient (6.7%)
(Table 4). The types of surgical procedures are shown in
Table 4. Although thromboprophylaxis was allowed at
the discretion of the investigator, only one patient
received such treatment (described in the Safety section).
PK/PD analysis
Eleven patients were included in the PK/PD analysis:
major surgery (n = 10); minor surgery (n = 1). The PK
parameters for VWF:RCo are shown in Table S2. As
expected for an IV bolus administration, median pre-dose
corrected VWF:RCo activity and VWF:Ag levels had
their peak shortly after administration (i.e. Cmax corre-
sponded with the first sampling time-point) and then
declined in an exponential manner (Fig. 1). Administra-
tion of rVWF alone stabilized endogenous FVIII, with a
gradual increase in FVIII:C levels as the infused rVWF
bound to the endogenous FVIII (Fig. 1A, B). After
administration of a single dose of rVWF, mean FVIII:C
levels showed substantial increases, from 20.6 IU dL1
pre-infusion to 34.1 IU dL1 at 1 h post-infusion,
67.5 IU dL1 at 6 h post-infusion and 86.9 IU dL1 at
12 h post-infusion for all patients (n = 11). For patients
with type 3 VWD (n = 5), FVIII:C levels increased from
1.8 IU dL1 pre-infusion to 15.6 IU dL1 at 1 h post-
infusion, 51.8 IU dL1 at 6 h post-infusion and
76 IU dL1 at 12 h post-infusion. Peak FVIII:C levels
were observed at 24 h post-infusion and gradually
declined over the next 48 h, but were still around
50 IU dL1 on average at 72 h post-infusion (Fig. 1A,
B). The mean hourly rise in endogenous FVIII:C levels
from pre-infusion to 6 h post-infusion was 8.44 IU dL1
(range, 4.43–11.57) for all patients and 9.01 IU dL1
(range, 7.54–10.88) for patients with type 3 VWD. For
patients with type 3 VWD, one reached > 60 IU dL1
FVIII within 6 h post-infusion, whereas the other four
patients reached 46–52 IU dL1 FVIII during the same
time period.
Hemostatic efficacy in all patients
Overall hemostatic efficacy, the primary endpoint, was
rated as ‘excellent’ or ‘good’ in 100% (n = 15/15) of
patients (90% CI, 81.9–100). Intraoperative hemostatic
efficacy was also rated as ‘excellent’ or ‘good’ in 100%
(n = 15/15) of patients (90% CI, 81.9–100). For patients
with type 3 VWD (n = 8), both the overall and intraoper-
ative hemostatic efficacy were rated as ‘excellent’ for
seven patients and ‘good’ in one patient.
Excluding infusions for the PK/PD analysis and those
given to treat bleeds and maintain hemostasis, patients
received a total of 104 surgical infusions of rVWF: 93
infusions (89.4%) of rVWF alone and 11 infusions
(10.6%) administered with rFVIII in five patients. Results
are summarized for the various time periods in Table 5
and presented by patient in Table 4. Of the five patients
who received 11 concomitant rVWF and rFVIII infu-
sions, three patients with type 3 VWD received a single
Table 3 Patient demographics and baseline clinical characteristics
Characteristic Total (N = 15)
Sex, n (%)
Male 7 (46.7)
Female 8 (53.3)
Age, median (range), years 40 (20–70)
Weight, median (range), kg 73.5 (52–127.2)
BMI, median (range), kg m2 25.6 (17.1–38)
VWD type, n (%)
1 3 (20)
2A 2 (13.3)
2B 1 (6.7)
2M 1 (6.7)
3 8 (53.3)
FVIII:C, mean (SD), IU dL1
All VWD types (N = 15) 16.4 (19.9)
Type 1 VWD (n = 3) 17 (4)
Type 2A VWD (n = 2) 34.5 (23.3)
Type 2B VWD (n = 1) 36
Type 2M VWD (n = 1) 66
Type 3 VWD (n = 8)* 3.0 (1.5)
Mean (SD) VWF:RCo, IU dL1
All VWD types (N = 14) 10.6 (13.3)
Type 1 VWD (n = 3) 14.3 (3.1)
Type 2A VWD (n = 2) 29.0 (26.9)
Type 2B VWD (n = 1) 23
Type 2M VWD (n = 1) 13
Type 3 VWD (n = 7)* 1.7 (4.5)
BMI, body mass index; FVIII:C, factor VIII activity; SD, standard
deviation; VWD, von Willebrand disease; VWF:RCo, von Wille-
brand factor ristocetin cofactor activity. *One patient with type 3
VWD had screening assessments performed with an inadequate
washout period. Therefore, the respective VWF:RCo result was
excluded. For FVIII:C, the test was repeated as an unscheduled visit
to confirm eligibility; the FVIII:C result from the unscheduled visit
is included in this table.
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co-administration 1 h before undergoing major surgery;
two of the three patients received rFVIII despite having
FVIII:C levels ≥ 60 IU dL1 (Table 4). The patient
undergoing molar extraction received six co-administra-
tions postoperatively; the postoperative pre-infusion
FVIII:C level ranged from 110 to 152 IU dL1 in five
cases. This patient’s peak FVIII:C level during this time
was 168 IU dL1. A patient with type 1 VWD received a
single co-administration intraoperatively for tooth extrac-
tion, although the intraoperative pre-infusion FVIII:C
level was 72 IU dL1. Lastly, a patient with type 3 VWD
received a single co-administration postoperatively for
radioisotope synovectomy, although the postoperative
pre-infusion FVIII:C level was 73 IU dL1. This patient
also received a postoperative dose of rVWF alone. Two
patients received no additional rVWF postoperatively.
Most patients (n = 12) received rVWF infusions no
more than once daily and, of these, 11 patients were not
dosed every day, with some infusions separated by 2–
9 days. Three patients undergoing major surgery (laparo-
scopic cholecystectomy in a type 2M patient, molar
extraction in a type 3 patient and prosthesis left ankle in
a type 3 patient) were treated twice daily on ≥ 1 day, with
most infusions given ~12 h apart.
The overall median surgical dose of rVWF was
220.4 IU kg1 (range, 63.8–648.4 IU kg1) (Table 6). The
mean actual intraoperative blood loss relative to predicted
blood loss was 70% (Table S3), rated ‘excellent’ for 13
patients and ‘good’ for two patients.
Hemostatic efficacy by surgery classification
Major surgery Overall hemostatic efficacy was rated
‘excellent’ or ‘good’ in 100% (n = 10/10) of major
surgeries: ‘excellent’ (n = 7/10); ‘good’ (n = 3/10). Intra-
operative hemostatic efficacy was also rated ‘excellent’ or
‘good’ in 100% (n = 10/10) of major surgeries: ‘excellent’
(n = 8/10); good (n = 2/10).
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Fig. 1. Median pre-dose adjusted von Willebrand factor ristocetin cofactor activity (VWF:RCo), von Willebrand factor antigen (VWF:Ag) and
endogenous factor VIII activity (FVIII:C) levels. (A) All patients with pharmacokinetic data available (n = 11). (B) Patients with type 3 von
Willebrand disease (n = 5).
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Seventy percent of patients (n = 7/10) undergoing
major surgery did not receive rFVIII co-administration.
Patients who underwent major surgery received a total of
87 surgical infusions of rVWF: 78 infusions (89.7%) of
rVWF alone and nine (10.3%) administered with rFVIII.
At ~1 h before surgery, seven rVWF infusions were
administered alone and three were co-administered with
rFVIII (all in type 3 VWD); doses are shown in Table 4.
No intraoperative doses of rVWF were administered.
During the postoperative period, 61 rVWF infusions were
administered alone and six were with rFVIII.
A median surgical rVWF dose of 307.6 IU kg1 (range,
125.2–648.4 IU kg1) was used in the 10 patients under-
going major surgery (Table 6). The mean actual intraop-
erative blood loss relative to predicted blood loss was
69% (Table S3): rated ‘excellent’ for eight patients and
‘good’ for two patients.
Minor/Oral surgery Overall and intraoperative hemo-
static efficacy were rated as ‘excellent’ in 100% (n = 4/4)
of patients who underwent minor surgery and were rated
as ‘good’ and ‘excellent’, respectively, in the patient who
underwent oral surgery.
Patients who underwent minor and oral surgery
received a total of 17 surgical infusions of rVWF: 15 infu-
sions (88.2%) of rVWF alone and two (11.8%) adminis-
tered with rFVIII. Doses of rVWF given to the patients
who underwent minor surgery and the one patient who
underwent oral surgery are shown in Table 4. One patient
with type 1 VWD who underwent oral surgery received
intraoperative co-administration of rVWF and rFVIII.
Postoperatively, three infusions of rVWF were adminis-
tered alone and one was administered with rFVIII for the
minor surgeries and two infusions of rVWF were admin-
istered alone for the oral surgery.
A median surgical rVWF dose of 119.9 IU kg1 (range,
63.8–217.3 IU kg1) was used in the four patients under-
going minor surgery and 108.4 IU kg1 was used in the
patient who underwent oral surgery (Table 6). The actual
intraoperative blood loss relative to predicted blood loss
is shown in Table S3, and was rated ‘excellent’ for all five
patients.
Safety
A total of 12 treatment-emergent AEs were reported in
six patients, including acne, anemia, deep vein thrombosis
(DVT), diverticulitis, dizziness, dry skin, headache, joint
swelling, nasopharyngitis, pelvic pain and peripheral swel-
ling. Among them, two patients had serious AEs (one
patient with diverticulitis and one patient with DVT).
None of these events were considered treatment related
by the investigator. The patient with the DVT was a 42-
year-old female with type 3 VWD and body mass index
of 24.6 kg m2 who underwent major total hip replace-
ment surgery and had overall hemostatic efficacy rated as
‘excellent’. A Duplex scan of lower extremity veins at the
start of surgery did not reveal any signs of thrombosis.
At the discretion of the investigator, the patient began
thromboprophylaxis with dabigatran 220 mg daily on the
day of surgery. A Duplex scan was performed according
to the standard of care at the local hospital on postopera-
tive day 4, although the patient was non-symptomatic.
This revealed a non-serious, asymptomatic left non-
Table 5 Surgical infusions of rVWF and rFVIII
Time of infusion
Number of
infusions
with rVWF
alone
Number of
infusions with
rVWF
and rFVIII
Number
of total
infusions
12–24 h before surgery 15 0 15
1 h before surgery 12 3 15
Intraoperative 0 1 1
Postoperative (0–14 days) 66 7 73
Total infusions, n (%) 93 (89.4) 11* (10.6) 104 (100.0)
rFVIII, recombinant factor VIII; rVWF, recombinant von Wille-
brand factor. *Only two of the 11 infusions were co-administered
with rFVIII because the target FVIII:C level was not met: one
patient with 36 IU dL1 within 3 h before surgery (prosthesis left
ankle) and one patient with 23 IU dL1 postoperatively (molar
extraction) (see text for details).
Table 6 Median rVWF exposure overall and by surgery classification
Dose
Surgery classification
Overall (N = 15)Minor (n = 4) Major (n = 10) Oral (n = 1)
Total infusions*, median (range), n 3 (2–4) 7.5 (4–15) 5 6 (2–15)
Exposure days, n (range) 3 (2–4) 6.5 (4–15) 4 6 (2–15)
Dose at 12–24 h before surgery, median (range), IU kg1 57.2 (55.0–59.9) 49.3 (37.4–57.6) 36.1 55.0 (36.1–59.9)
Dose within 1–2 h before surgery, median (range), IU kg1 39.3 (8.0–46.4) 37.6 (15.7–82.7) 18.1 35.8 (8.0–82.7)
Intraoperative dose, median (range), IU kg1 0 0 18.1 18.1
Postoperative doses, median (range), IU kg1 79.3 (42.8–115.9) 214.8 (47.7–533.3) 36.1 189.8 (36.1–533.3)
Total surgical dose, median (range), IU kg1 119.9 (63.8–217.3) 307.6 (125.2–648.4) 108.4 220.4 (63.8–648.4)
rVWF, recombinant von Willebrand factor. *Total number of preoperative doses (12–24 h before surgery), preoperative doses (within 1–2 h
before surgery), intraoperative doses and postoperative doses.
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occlusive thrombosis of common and deep femoral veins.
The patient’s ADAMTS-13 level was 37% on this day.
Thromboprophylaxis was changed from dabigatran to
enoxaparin 80 mg twice daily (with treatment continuing
until discharge on day 17 when she was placed on
rivaroxaban 20 mg daily).
Continuation of the DVT event as a floating thrombus
of the left common femoral vein was seen via Duplex
scan on postoperative day 8, was considered a serious
AE, and resulted in placement of a retrievable filter in the
inferior vena cava without complications. The event sub-
sequently resolved (the filter was removed 2 months later)
and was considered by the investigator to be related to
the numerous risk factors (i.e. obesity, surgical procedure
and immobilization) of the patient rather than to rVWF
or rFVIII (peak level, 158 IU dL1 on postoperative day
3). Despite the existence of these confounding factors, the
continued administration of treatment in the postopera-
tive period led the study sponsor to reassess this event as
‘possibly related’ to treatment.
No deaths or severe allergic reactions were reported.
No neutralizing antibodies to VWF, FVIII or Chinese
hamster ovary proteins, Furin or murine IgG were
detected. One patient with type 3 VWD who underwent a
total knee replacement and received an intraoperative
transfusion of packed red blood cells (500 mL volume)
had a positive result for binding antibodies to VWF on
postoperative days 7, 8, 10 and 11; these antibodies were
non-inhibitory and had no effect on VWF:RCo.
Discussion
This is the first study evaluating a novel rVWF factor
concentrate in patients with severe VWD undergoing sur-
gery. The overall and intraoperative hemostatic efficacy
of rVWF (with/without co-administration of rFVIII) was
assessed relative to the expected level of bleeding in peo-
ple without VWD undergoing similar surgery. The pri-
mary endpoint was achieved, as overall hemostatic
efficacy was rated as ‘excellent’ or ‘good’ for all 15
patients treated with rVWF, and intraoperative hemo-
static efficacy was rated as ‘excellent’ or ‘good’ for all
surgeries.
During the study, 80% (12/15) of patients did not
receive any preoperative FVIII and 67% (10/15) of
patients and 70% (7/10) of the major surgeries performed
were treated with rVWF alone. Five patients received 11
infusions that included both rVWF and rFVIII. Only two
of these infusions were performed when the FVIII:C level
was < 60 IU dL1; the remaining nine were performed
despite the FVIII:C level being above the target level.
The doses of rFVIII used during co-administration were
small (four infusions of 7.6 IU kg1, two infusions of
15.2 IU kg1, and one infusion each of 8.1, 14.5, 17.4,
22.8 and 42.3 IU kg1) to maintain a specific FVIII:C
level, rather than to achieve a large increase. These results
can be attributed to the PK/PD findings, which showed
substantial increases in endogenous FVIII:C levels after
administration of rVWF alone, with all patients achieving
mean FVIII:C > 60 IU dL1 by 6 h post-infusion. Mean
endogenous FVIII:C levels were 28.5 IU dL1 as early as
30 min post-infusion, 67.5 IU dL1 6 h post-infusion and
90.6 IU dL1 24 h post-infusion, with corresponding
levels of 10.8, 51.8 and 83.4 IU dL1 in patients with
type 3 VWD. Despite having mean FVIII:C levels
< 2 IU dL1 at baseline, administration of rVWF alone
allowed patients to achieve target VWF:RCo and
FVIII: C levels quickly. Compared with type 3 patients,
those with type 1 and 2 started with higher baseline levels
of FVIII:C, and therefore achieved target levels more
rapidly.
Our findings are consistent with previous studies show-
ing that replacement of VWF with a plasma-derived fac-
tor concentrate with very low levels of FVIII immediately
stabilizes endogenous FVIII and that there is a gradual
increase in FVIII:C levels as the infused VWF binds
newly synthesized protein, thus leading to hemostatic
levels within several hours post-infusion [1,16]. Consider-
ing some type 1 and 2 patients will already be at, or
nearly at, target FVIII:C levels preoperatively, our results
suggest they may only need the rVWF infusion at 1 h
before surgery. These data also suggest that the majority
of postoperative infusions of once-daily rVWF alone sus-
tained FVIII:C at hemostatically effective levels.
The lack of FVIII in rVWF may be especially impor-
tant in the surgical setting, during long-term prophylaxis,
in the elderly and in the obstetric setting [12,17]. Physi-
cians have the flexibility to choose whether or not to co-
administer FVIII. In this study, because of the rapid and
sustained increases in endogenous FVIII:C levels after
infusion of rVWF alone, the vast majority of infusions
did not include any exogenous FVIII. As the administra-
tion of exogenous FVIII was at the discretion of the
physician, lack of rapid access to the measurement of
FVIII:C levels at some centers, as well as the length and
intensity of individual surgical procedures, could have
factored into the decision to administer the drug.
The acceptable safety profile of rVWF in this study was
consistent with that seen in the Phase 3 on-demand trial
[13]. In the current study, 12 treatment-emergent AEs were
reported in six patients who received 104 surgical infusions
of rVWF. There were no reports of severe allergic reac-
tions, neutralizing or inhibitory antibody development, or
deaths. There was a single report of DVT in one patient.
The patient received thromboprophylaxis to reduce the
risk of DVT. However, obesity [18,19] and gender (female
vs male) [19–22] are independent risk factors for DVT
development in patients undergoing orthopedic surgery.
This patient also had a low ADAMTS-13 level around the
time of the event. The individual patient risk factors, in
addition to post-surgery administration of rVWF to main-
tain hemostasis, confound the situation. Recombinant von
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Willebrand factor contains a greater proportion of ULMs
versus pdVWFs, during initial infusion [3,4,11,23]. How-
ever, they undergo rapid proteolysis, indicating appropri-
ate susceptibility of rVWF to physiologic regulation by
ADAMTS-13 [14]. Therefore, in the presence of physio-
logic levels of ADAMTS-13, the prothrombotic potential
of ULMs would be expected to be low. Furthermore, the
absence of both VWF and ADAMTS-13 in a single patient
is thought to be extremely rare. Therefore, the event was
considered ‘possibly related’ to treatment by the study
sponsor.
The primary limitation of this study was the small sam-
ple size, limiting the generalizability of the results. How-
ever, similar results were observed across study centers,
potentially indicating the robustness of rVWF for treating
surgical bleeding in VWD. Therefore, these findings
should be confirmed in a larger study or with real-world
data.
Clinical implications and conclusions
These data support the efficacy and safety profile of
rVWF (with/without co-administration of rFVIII) in
achieving hemostasis in patients with severe VWD who
were undergoing elective surgery. In this study, infusion
of rVWF alone resulted in hemostatically effective levels
of endogenous FVIII after 6 h, that were sustained for
72–96 h. These data allow physicians to consider the risk
factors for each patient and to decide whether rVWF
should be administered alone or with rFVIII during and
after surgery. Many clinicians avoid the use of plasma-
derived VWF/FVIII concentrates; therefore, a recombi-
nant product may be especially important to them. In
most cases, infusions of rVWF alone no more than once
daily were sufficient to maintain stable endogenous
FVIII:C levels within the target range. This was likely to
be the result of either reduced clearance or the extended
half-life of rVWF. Patient management can therefore
focus on achieving optimal efficacy without concern over
unnecessary exposure to excessive FVIII levels and its
associated risks. This may be of particular benefit in
patients with high baseline FVIII levels or malignancies,
the elderly, and those undergoing major surgeries. Based
on our experience with elective surgery, it is recommended
that during emergency surgery baseline VWF:RCo and
FVIII:C levels should be assessed prior to surgery and
intraoperative peak plasma levels, as indicated for elective
surgery, should be targeted by infusion of adequate
doses of rVWF and, as needed, rFVIII. The presence of
ULMs in rVWF are likely to contribute to the rapid sta-
bilization of endogenous FVIII:C levels. This could have
important clinical implications, potentially reducing the
need to administer exogenous FVIII and delaying admis-
sion until the day of surgery. It remains to be seen
whether current guidelines [7] for the use of VWF concen-
trates will apply to rVWF, given the efficacy and
extended normalization of FVIII:C levels observed in this
small study population.
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